Welcome to our dedicated page for Indivior PLC Ordinary Shares news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior PLC Ordinary Shares stock.
Indivior PLC (LSE/Nasdaq: INDV) is a global leader in developing and manufacturing prescription drugs aimed at treating substance use disorders and serious mental illnesses. Headquartered in Richmond, VA, the company employs over 1,000 individuals globally and its products are available in 37 countries worldwide. Indivior's core products include Sublocade, Perseris, Suboxone, and Opvee.
Indivior's major revenue streams are driven by markets in the United States, the United Kingdom, and other international regions. The company continually strives to offer innovative treatments, such as its recent Sublocade injection, which has proven efficient in reducing opioid overdoses in clinical trials. Other notable projects include the development of INDV-2000, a non-opioid treatment for opioid use disorder, and the strategic acquisition of Alar Pharmaceuticals' portfolio of long-acting injectable formulations.
Indivior is committed to transforming the landscape of addiction treatment through evidence-based solutions. Its recent achievements include the publication of a retrospective chart review in the Journal of Addiction Medicine, showcasing Sublocade's efficacy in reducing opioid overdoses in Canada.
- Financial Performance: Indivior consistently shares its quarterly financial results, with recent announcements showcasing solid revenue growth and strategic investments.
- Partnerships: The company has secured exclusive global rights to develop and commercialize long-acting injectable formulations from Alar Pharmaceuticals, enhancing its product pipeline.
- Research & Development: Indivior is actively involved in R&D to address a broader spectrum of substance use disorders, including alcohol and cannabis use disorders, backed by substantial NIH-HEAL grants.
- Safety: The company places a strong emphasis on safety, providing comprehensive safety information for all its products, ensuring that both healthcare providers and patients are well-informed.
With a vision of making evidence-based treatments accessible globally, Indivior continues to lead in the field of addiction treatment, offering hope and improved health outcomes for millions.
Indivior has published new data comparing the effectiveness of intranasal (IN) nalmefene (OPVEE 2.7mg) and IN naloxone (4 mg) in reversing synthetic opioid overdoses. The study, using a validated translational model, shows that a single dose of OPVEE significantly reduces simulated cardiac arrests caused by fentanyl and carfentanil overdoses compared to naloxone. For instance, a single OPVEE dose reduced the cardiac arrest rate to 12% in chronic opioid users, whereas naloxone reduced it to 47%. Multiple naloxone doses were required to match OPVEE's effectiveness. The simulation involved 2000 virtual patients, highlighting OPVEE's superior performance in reversing overdoses, which is critical given the high rates of synthetic opioid-linked fatalities in the US. These findings could inform better emergency response strategies.
Indivior has initiated dosing of the first subject in a Phase 2 study of INDV-2000, a non-opioid treatment for Opioid Use Disorder (OUD). This double-blind, placebo-controlled trial will assess the safety and efficacy of INDV-2000 over three months in participants with moderate to severe OUD. Supported by an NIH-HEAL grant, the study aims to determine the dose-response relationship for INDV-2000, an orexin-1 receptor antagonist demonstrated to reduce opioid self-administration in animal studies. INDV-2000 offers a potential new treatment option for individuals seeking non-opioid alternatives.
Indivior, a leading addiction treatment company, will host an analyst teach-in event in New York City, confirming its FY 2024 guidance. The company expects net revenue between $1,240m and $1,330m, an 18% increase from FY 2023. SUBLOCADE revenue is projected at $820m to $880m, a 35% rise. OPVEE revenue is anticipated to be $15m to $25m, and PERSERIS revenue is forecasted at $55m to $65m, a 43% increase. SUBOXONE Film market share is expected to decline by 1-2 percentage points. Adjusted gross margin is estimated to be in the low to mid-80s range.
Adjusted SG&A expenses are projected at $575m to $590m, with R&D expenses between $120m and $130m. Adjusted operating profit is expected to be $330m to $380m. The event will be webcast and aims to provide an in-depth overview of Indivior's growth and value creation strategies.
FAQ
What is the current stock price of Indivior PLC Ordinary Shares (INDV)?
What is the market cap of Indivior PLC Ordinary Shares (INDV)?
What does Indivior PLC do?
What are Indivior's main products?
Where does Indivior generate most of its revenue?
What recent studies have been published about Indivior's products?
What is INDV-2000?
What recent acquisitions has Indivior made?
Where is Indivior headquartered?
How many employees does Indivior have?
What are some safety considerations for Indivior's products?
How can I stay updated on Indivior's financial performance?
